ADHD is not a deficit of attention. It is a disorder of attention regulation.

ADHD — attention-deficit/hyperactivity disorder — is a neurodevelopmental condition defined by persistent patterns of inattention, hyperactivity, and impulsivity that impair function at home, at school, or at work. The first word of the name is the misleading one. People with ADHD do not lack attention. They cannot reliably direct it toward tasks that do not interest them, and they cannot reliably disengage it from tasks that do. It is a dysregulation of attention, not a deficit.

The biology involves the prefrontal cortex — the brain region responsible for planning, impulse control, working memory, and time perception — and its connections to the striatum and limbic system. These circuits depend heavily on the neurotransmitters dopamine and norepinephrine. Brain imaging studies have documented consistent differences in the size and activity of these regions in people with ADHD, and genetic studies have identified dozens of risk variants, many in genes that regulate dopamine signaling.

Three presentations are recognized. The predominantly inattentive presentation — sometimes called "ADD" in older terminology — is characterized by forgetfulness, difficulty organizing tasks, and losing track of time. The predominantly hyperactive/impulsive presentation is characterized by restlessness, interrupting, and difficulty waiting. The combined presentation has features of both and is the most common in children.

Two things are worth stating plainly. First, ADHD is a real diagnosis, recognized by every major medical body and confirmed by decades of research. Second, it is not a moral failing. The person who leaves tasks half-finished, loses keys repeatedly, or cannot start a project that matters to them is not choosing this pattern — the circuits that would allow sustained direction of attention are working less reliably.

A note about misuse that comes up in nearly every adult ADHD discussion: when prescribed at therapeutic doses to a person who actually has ADHD, stimulants do not typically cause euphoria. They tend to produce calm, focus, and reduced restlessness — a paradoxical effect that was one of the earliest clinical observations suggesting ADHD has a distinct neurological basis. Euphoria at prescribed doses, if it occurs, is usually a sign that the dose is too high or the diagnosis does not fit.

The misuse concern is real for a small subset of patients — those with a personal history of stimulant or cocaine use disorder. For that group, non-stimulant options like atomoxetine or guanfacine are usually preferred. But for the majority of patients, untreated ADHD increases the risk of substance use, and effective treatment reduces it rather than increases it.

Two practical consequences follow from the curves. First, the "crash" that some patients describe in the late afternoon is usually the tail end of an IR dose wearing off — plasma levels fall more steeply than symptoms require, producing a sensation of sudden fatigue or irritability. ER formulations smooth this out considerably.

Second, no single formulation covers the entire day at a uniform level. Patients who need coverage past 6 or 7 p.m. — for homework, driving, parenting, or evening work — often use a small IR dose in the afternoon alongside a morning ER dose. This is standard practice, not a sign that the primary medication is failing.

Several ADHD medications are available as low-cost generics in the United States. Generic methylphenidate, dextroamphetamine, and atomoxetine are all priced well below their brand versions. Extended-release formulations are more complicated: some have generics (Concerta has authorized generics, Adderall XR has generics), and others remain brand-only because of formulation patents or manufacturing complexity. Vyvanse, despite being one of the most prescribed ADHD medications, went generic recently but supply and pricing have been inconsistent.

What matters in practice: the same generic tablet can cost five to ten times more at one licensed pharmacy than another, and this is especially true for controlled substances like stimulants, where pharmacies have different stock patterns and prices. A live prescription price comparison shows the current range in about two minutes, and the same logic applies to every generic on a patient's list. For a first-time online refill, the process is documented step by step in this how to order prescriptions online guide — prescription first, licensed seller second, small first order third.

Two practical notes specific to ADHD:

First, controlled substances cannot always be filled by online pharmacies. Schedule II stimulants are subject to additional restrictions, and many online sellers do not dispense them at all. This is legal and expected — it does not indicate a problem with the seller.

Second, do not skip doses to stretch a prescription. This is a common response to cost pressure with ADHD medication, and it reliably produces the exact symptom return that leads patients to conclude the medication "doesn't work." If the cost is prohibitive, tell the prescriber — there is usually a lower-cost generic, a manufacturer patient assistance program, or a non-stimulant alternative that fits the budget.

Before filling from any seller — online or local — verify them. A working VIPPS seal that resolves to a live NABP record, a real U.S. street address, and a prescription requirement that cannot be waived. A transparency page like this one about Metformin4You is a reasonable example of the standard to expect.